Overview

Phase IIA Study in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Olanzapine